Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user reported significant hair regrowth after 4 months using Dutasteride, oral and topical Minoxidil, Nizoral shampoo, and dermastamping. They experienced minor side effects but noted consistent progress and regrowth, especially at the hairline and temples.

The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.

The user shared a 14-month progress update using a 4-in-1 topical solution containing 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, applied nightly. They reported good results without microneedling and prefer the topical form over oral medication.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A 24-year-old shares their positive 4-month progress using 0.5 mg oral finasteride and 5% topical minoxidil for hair loss, reporting no significant side effects. Other users discuss similar experiences and regimens, with some expressing concerns about potential side effects.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The user shared progress pictures after 4 months of using 5% topical minoxidil and microneedling for hair loss. They discussed their positive results and experiences with these treatments.

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user saw significant hair regrowth after using rosemary-castor oil, scalp massages, a derma roller, biotin shampoo, minoxidil-finasteride spray, and a PRP injection. They plan to continue this routine.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

The user has been using 0.5mg finasteride daily for 4 years and is considering adding minoxidil, either oral or topical, to improve hairline density. They are also contemplating a hair transplant and have been using derma rolling and ketoconazole inconsistently.

The user experienced significant hair regrowth using a regimen of minoxidil 5% twice daily, finasteride 1 mg daily, microneedling, ketoconazole 2% twice a week, and occasional castor and coconut oil, along with daily scalp massages. They are optimistic about reversing their Norwood 5/6 hair loss.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user has been using Roman 3-in-1 topical treatment (finasteride 0.3%, minoxidil 6%, tretinoin 0.025%) and a 0.25 mm dermaroller for four months to address crown thinning. They are seeking advice on whether to continue with the current regimen, switch to oral finasteride, or try dutasteride for better results.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

A 33-year-old male shared his 4-month hair growth progress using 1mg finasteride and 2.5mg minoxidil daily, along with hair supplements and a serum containing Redensyl, Anagain, Capixyl, and Procapil. He reported thickening of existing hair and new hair growth without side effects.

A 41-year-old doctor shared his positive experience with a 4,100 graft hair transplant, highlighting the importance of a skilled doctor for a natural hairline. He mentioned a confidence boost and the occasional use of finasteride post-transplant.

The user reported positive results with thicker and denser hair after four months of taking 1mg oral finasteride daily, without using minoxidil. Some users discussed potential side effects like mild testicular ache and debated the timing and benefits of adding minoxidil to the regimen.